Fattore, Luigi
Malpicci, Debora
Milite, Ciro
Castellano, Sabrina
Sbardella, Gianluca
Botti, Gerardo
Ascierto, Paolo A.
Mancini, Rita
Ciliberto, Gennaro
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG15216, IG17009)
Regione Lazio (n.85-2017-13750)
Article History
Received: 28 April 2020
Accepted: 23 July 2020
First Online: 15 September 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: All The authors declare no conflict of interest with the exception of P.A.A. P.A.A. has advisory/consultant role for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco. P.A.A. receives research funds from BMS, Roche-Genentech, Array and travel support from MSD. The funders of this study had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.